ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year.
Related Posts
Dave & Buster’s Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts
Dave & Buster's Entertainment, Inc. (NASDAQ: PLAY) is expected to release earnings results for its fourth quarter, after the closing bell on April 2, 2024.
Seaport Global Initiates Coverage On Jushi Holdings with Buy Rating, Announces Price Target of $3
Seaport Global analyst Sonny Randhawa initiates coverage on Jushi Holdings (OTC:JUSHF) with a Buy rating and announces Price Target of $3.